Palvella Therapeutics, Inc. SEC filings PVLA
Palvella Therapeutics, Inc. has 814 filings in SEC EDGAR's recent list, going back to Aug 20, 2013. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 4, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 28, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Jan 29, 2026 | — |
| CORRESP | Letter to the SEC | Jan 27, 2026 | — |
| UPLOAD | Letter from the SEC | Jan 5, 2026 | — |
| EFFECT | Filing | Jan 16, 2025 | — |
| CORRESP | Letter to the SEC | Jan 15, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 3, 2025 | — |
| 425 | Form 425 | Dec 12, 2024 | — |
| 425 | Form 425 | Dec 3, 2024 | — |
| SEC STAFF LETTER | Filing | Nov 12, 2024 | — |
| EFFECT | Filing | Nov 8, 2024 | — |
| 425 | Form 425 | Nov 7, 2024 | — |
| CORRESP | Letter to the SEC | Nov 7, 2024 | — |
| CORRESP | Letter to the SEC | Nov 5, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 4, 2024 | — |
| CORRESP | Letter to the SEC | Oct 29, 2024 | — |
| SEC STAFF LETTER | Filing | Oct 25, 2024 | — |
| UPLOAD | Letter from the SEC | Oct 25, 2024 | — |
| 425 | Form 425 | Oct 17, 2024 | — |
| CORRESP | Letter to the SEC | Oct 15, 2024 | — |
| 425 | Form 425 | Oct 15, 2024 | — |
| UPLOAD | Letter from the SEC | Oct 9, 2024 | — |
| 425 | Form 425 | Oct 3, 2024 | — |
| CORRESP | Letter to the SEC | Sep 23, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 6, 2024 | — |
| 425 | Form 425 | Aug 8, 2024 | — |
| 425 | Form 425 | Jul 24, 2024 | — |
| CT ORDER | Filing | Jan 3, 2023 | — |
| CT ORDER | Filing | Jan 3, 2023 | — |
| CT ORDER | Filing | Jan 3, 2023 | — |
| CT ORDER | Filing | Dec 16, 2022 | — |
| EFFECT | Filing | Aug 13, 2021 | — |
| CORRESP | Letter to the SEC | Aug 11, 2021 | — |
| UPLOAD | Letter from the SEC | Aug 11, 2021 | — |
| EFFECT | Filing | May 28, 2021 | — |
| CORRESP | Letter to the SEC | May 26, 2021 | — |
| UPLOAD | Letter from the SEC | May 19, 2021 | — |
| CT ORDER | Filing | Aug 7, 2020 | — |
| CT ORDER | Filing | May 12, 2020 | — |
| CT ORDER | Filing | Jan 21, 2020 | — |
| CT ORDER | Filing | Jan 21, 2020 | — |
| EFFECT | Filing | Dec 12, 2019 | — |
| CORRESP | Letter to the SEC | Dec 11, 2019 | — |
| UPLOAD | Letter from the SEC | Dec 9, 2019 | — |
| D | Filing | Nov 20, 2019 | — |
| CT ORDER | Filing | Jul 11, 2019 | — |
| CT ORDER | Filing | May 14, 2019 | — |
| EFFECT | Filing | Aug 24, 2018 | — |
| CORRESP | Letter to the SEC | Aug 21, 2018 | — |
| UPLOAD | Letter from the SEC | Aug 15, 2018 | — |
| CT ORDER | Filing | Aug 6, 2018 | — |
| CT ORDER | Filing | May 1, 2018 | — |
| CT ORDER | Filing | May 1, 2018 | — |
| CT ORDER | Filing | May 1, 2018 | — |
| CT ORDER | Filing | Aug 19, 2016 | — |
| EFFECT | Filing | Aug 3, 2016 | — |
| EFFECT | Filing | Aug 3, 2016 | — |
| EFFECT | Filing | Aug 3, 2016 | — |
| CORRESP | Letter to the SEC | Aug 2, 2016 | — |
| CORRESP | Letter to the SEC | Aug 2, 2016 | — |
| CORRESP | Letter to the SEC | Aug 2, 2016 | — |
| CT ORDER | Filing | Jul 22, 2016 | — |
| CT ORDER | Filing | Jul 22, 2016 | — |
| D | Filing | Jun 15, 2016 | — |
| EFFECT | Filing | Jun 29, 2015 | — |
| CORRESP | Letter to the SEC | Jun 26, 2015 | — |
| CORRESP | Letter to the SEC | Jun 26, 2015 | — |
| CERTNAS | Auto-generated paper document | Jun 25, 2015 | — |
| 8-A12B | Form 8-a | Jun 24, 2015 | — |
| CORRESP | Letter to the SEC | Jun 23, 2015 | — |
| CORRESP | Letter to the SEC | Jun 23, 2015 | — |
| UPLOAD | Letter from the SEC | Jun 16, 2015 | — |
| CT ORDER | Filing | Jun 2, 2015 | — |
| EFFECT | Filing | May 11, 2015 | — |
| CORRESP | Letter to the SEC | May 8, 2015 | — |
| CT ORDER | Filing | May 7, 2015 | — |
| UPLOAD | Letter from the SEC | Mar 17, 2015 | — |
| D | Filing | Dec 31, 2014 | — |
| D | Filing | Dec 31, 2014 | — |
| EFFECT | Filing | Jan 28, 2014 | — |
| CORRESP | Letter to the SEC | Jan 24, 2014 | — |
| UPLOAD | Letter from the SEC | Jan 6, 2014 | — |
| UPLOAD | Letter from the SEC | Dec 6, 2013 | — |
| UPLOAD | Letter from the SEC | Oct 15, 2013 | — |
| UPLOAD | Letter from the SEC | Sep 17, 2013 | — |
Showing 84 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PVLA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Wayne, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1583648
- Former names
- PIERIS PHARMACEUTICALS, INC. (until Dec 12, 2024); Marika Inc. (until Dec 18, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.